195 related articles for article (PubMed ID: 29190894)
1. MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells.
Kaehler M; Ruemenapp J; Gonnermann D; Nagel I; Bruhn O; Haenisch S; Ammerpohl O; Wesch D; Cascorbi I; Bruckmueller H
Oncotarget; 2017 Nov; 8(54):92018-92031. PubMed ID: 29190894
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
4. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
6. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
7. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21.
Zhou X; Yuan P; Liu Q; Liu Z
Biomol Ther (Seoul); 2017 Sep; 25(5):490-496. PubMed ID: 28190319
[TBL] [Abstract][Full Text] [Related]
9. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Kaymaz BT; Günel NS; Ceyhan M; Çetintaş VB; Özel B; Yandım MK; Kıpçak S; Aktan Ç; Gökbulut AA; Baran Y; Can BK
Tumour Biol; 2015 Sep; 36(10):7915-27. PubMed ID: 25953263
[TBL] [Abstract][Full Text] [Related]
10. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
11. miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
Rittavee Y; Artus J; Desterke C; Simanic I; de Souza LEB; Riccaldi S; Coignard S; Ijjeh Y; Hugues P; Bennaceur-Griscelli A; Turhan AG; Foudi A
Exp Hematol; 2023 Feb; 118():40-52. PubMed ID: 36535407
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
Shukla S; Kouanda A; Silverton L; Talele TT; Ambudkar SV
Mol Pharm; 2014 Jul; 11(7):2313-22. PubMed ID: 24865254
[TBL] [Abstract][Full Text] [Related]
13. Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
Malhotra H; Sharma P; Malhotra B; Bhargava S; Jasuja S; Kumar M
Indian J Med Res; 2015 Aug; 142(2):175-82. PubMed ID: 26354214
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
16. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
17. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Brendel C; Scharenberg C; Dohse M; Robey RW; Bates SE; Shukla S; Ambudkar SV; Wang Y; Wennemuth G; Burchert A; Boudriot U; Neubauer A
Leukemia; 2007 Jun; 21(6):1267-75. PubMed ID: 17519960
[TBL] [Abstract][Full Text] [Related]
19. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.
Jordanides NE; Jorgensen HG; Holyoake TL; Mountford JC
Blood; 2006 Aug; 108(4):1370-3. PubMed ID: 16627755
[TBL] [Abstract][Full Text] [Related]
20. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
